Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of
Fosun International, have been named Asia's Best CEOs by the magazine Corporate Governance Asia. The announcement was made during the 14th Asian Excellence Award ceremony held on May 31, 2024. Fosun International also garnered the Sustainable Asia Award and the Best Corporate Communications Award.
Corporate Governance Asia is a prominent publication focused on corporate governance in the Asia Pacific region. The awards highlight companies and leaders excelling in financial performance, governance, social responsibility, environmental stewardship, communication, and investor relations. Other prestigious recipients include Sino Land, Sun Hung Kai Properties, New World Development,
Bank of China (Hong Kong),
China Mobile,
China Telecom, China Unicom,
CNOOC,
PetroChina, and China Communications Services.
The awards recognize businesses that have achieved steady growth while excelling in Environmental, Social, and Governance (ESG) metrics, despite challenging economic conditions. Corporate Governance Asia emphasized the necessity for companies to have robust strategic planning and operational resilience to ensure sustainable development amid a volatile global economy.
In 2023,
Fosun maintained its strategic focus on core businesses, achieving steady progress and strengthening its operational capabilities in key industries. Despite the unfavorable global economic environment influenced by geopolitical factors, the company demonstrated strong performance. Chen Qiyu and Xu Xiaoliang were commended for their leadership, which has driven both business growth and enhanced sustainable development at Fosun. Their efforts in improving the Group's ESG performance and leveraging Fosun's global industrial ecosystem were particularly noted.
Chen Qiyu, Executive Director and Co-CEO, emphasized Fosun's commitment to technology-driven innovation and social contribution. He highlighted the breakthrough achievements of anti-
cancer drugs developed by Fosun, including
Yi Kai Da, the first CAR-T cell therapy product approved in Mainland China. This innovation aims to significantly improve the lives of
lymphoma patients, contributing to Fosun's goal of helping people live healthily beyond the age of 121. Chen also stressed the company's dedication to its 'dual carbon' goals to enhance sustainable development.
Xu Xiaoliang, Executive Director and Co-CEO, discussed Fosun's globalization strategy. He pointed out that Fosun leverages global resources to bring high-quality products and services worldwide. Xu highlighted the Group's efforts in promoting Chinese culture, such as the Yuyuan Garden Lantern Festival held in Paris, emphasizing Fosun's blend of business globalization and cultural exchange. Looking forward, Xu stated that Fosun would continue to enhance its global operations and corporate responsibility.
Fosun's exceptional ESG performance has been widely recognized. The Group has been strengthening its ESG framework, improving climate response, accelerating green development, and fulfilling its corporate social responsibilities. These efforts have earned Fosun the Sustainable Asia Award and the Best Corporate Communications Award. The company has also been acknowledged for its consistent AA rating by MSCI ESG for three consecutive years, the highest rating for a conglomerate in Greater China. Additionally, Fosun's HSI ESG rating improved to AA-, and it was included in the Hang Seng Corporate Sustainability Index. The company also ranked in the top 6% globally in the S&P Global Corporate Sustainability Assessment and was featured in the S&P Global's Sustainability Yearbook 2024 as an "Industry Mover." Furthermore, Fosun has been a constituent of the FTSE4Good Index Series for two consecutive years.
Fosun's continuous commitment to ESG and sustainable development, even amid challenging post-pandemic economic conditions, reflects its dedication to creating a better world.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
